Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?

Michelle M. Mielke, Norman J. Haughey

Research output: Contribution to journalReview articlepeer-review

39 Scopus citations


Understanding the etiopathological processes of Alzheimer's disease (AD) in the preclinical and early clinical stages will be important in developing new therapeutic targets and biomarkers. There is growing consensus that nonamyloid targets will be necessary to reverse or slow AD progression. Lipidomic, metabolomic and targeted approaches have identified pathways and products of sphingolipid metabolism that are altered early in the course of AD and contribute to the neuropathological alterations associated with AD, including amyloid-β production, tau formation and neurodegeneration. In this article, we briefly review the current literature on the role of sphingolipids in the underlying pathophysiology of AD, and then discuss the current state of translating these findings to clinical populations and the potential utility of plasma sphingolipids as diagnostic and/or prognostic indicators of AD.

Original languageEnglish (US)
Pages (from-to)525-536
Number of pages12
JournalClinical Lipidology
Issue number5
StatePublished - Oct 2012


  • Alzheimer's disease
  • amyloid
  • biomarker
  • blood
  • ceramide
  • lipid
  • neurodegeneration
  • sphingolipid
  • tau

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Could plasma sphingolipids be diagnostic or prognostic biomarkers for Alzheimer's disease?'. Together they form a unique fingerprint.

Cite this